Srinagar, Sept. 17 -- The announcement of Russia's new mRNA-based cancer vaccine, Enteromix, has stirred global hope. Claimed to show 100% efficacy and safety in early clinical trials, it comes as the world continues its long battle against one of humanity's deadliest diseases. The vaccine is designed to train the immune system to recognize and destroy cancer cells, sparing healthy tissue. If all goes well in the bigger trials, it could usher in a new era in oncology where malignancy is combated by the body's natural defences.

This breakthrough comes in the wake of the development of a drug in 2022 when twelve rectal cancer patients treated with dostarlimab were found to be completely tumor-free after six months of therapy. That trial, ...